dabigatran has been researched along with pantoprazole in 9 studies
| Studies (dabigatran) | Trials (dabigatran) | Recent Studies (post-2010) (dabigatran) | Studies (pantoprazole) | Trials (pantoprazole) | Recent Studies (post-2010) (pantoprazole) |
|---|---|---|---|---|---|
| 3,887 | 261 | 3,490 | 1,467 | 476 | 579 |
| Protein | Taxonomy | dabigatran (IC50) | pantoprazole (IC50) |
|---|---|---|---|
| Solute carrier family 22 member 2 | Homo sapiens (human) | 1.5 | |
| Multidrug and toxin extrusion protein 1 | Homo sapiens (human) | 2.8 | |
| Broad substrate specificity ATP-binding cassette transporter ABCG2 | Homo sapiens (human) | 7.75 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (33.33) | 29.6817 |
| 2010's | 4 (44.44) | 24.3611 |
| 2020's | 2 (22.22) | 2.80 |
| Authors | Studies |
|---|---|
| Giacomini, KM; Huang, Y; Khuri, N; Kido, Y; Kosaka, A; Morrissey, KM; Sali, A; Wittwer, MB; Zhang, X; Zur, AA | 1 |
| Ahnfelt, L; Dahl, OE; Eriksson, BI; Nehmiz, G; Rathgen, K; Stähle, H; Stangier, J; Svärd, R | 1 |
| Fuhr, R; Rathgen, K; Stähle, H; Stangier, J | 1 |
| Stangier, J | 1 |
| Meesmann, M; Scheppach, W | 1 |
| Accassat, S; Basset, T; Bertoletti, L; Delavenne, X; Hodin, S; Mismetti, P; Ollier, E | 1 |
| Bánovčin, P; Bolek, T; Galajda, P; Kubisz, P; Lipták, P; Mokán, M; Samoš, M; Schnierer, M; Škorňová, I; Staško, J; Urban, L | 1 |
| Bánovčin, P; Bolek, T; Galajda, P; Hyrdel, R; Kubisz, P; Mokáň, M; Nosáková, L; Samoš, M; Schnierer, M; Škorňová, I; Stasko, J | 1 |
| Abad-Santos, F; Almenara, S; Koller, D; Mejía, G; Navares-Gómez, M; Ochoa, D; Román, M; Saiz-Rodríguez, M; Soria-Chacartegui, P; Zubiaur, P | 1 |
1 review(s) available for dabigatran and pantoprazole
| Article | Year |
|---|---|
Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Anti-Ulcer Agents; Anticoagulants; Benzimidazoles; Biological Availability; Dabigatran; Drug Interactions; Food-Drug Interactions; Humans; Liver Diseases; Pantoprazole; Prodrugs; Pyridines; Thrombin | 2008 |
3 trial(s) available for dabigatran and pantoprazole
| Article | Year |
|---|---|
Pharmacokinetic profile of the oral direct thrombin inhibitor dabigatran etexilate in healthy volunteers and patients undergoing total hip replacement.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Absorption; Administration, Oral; Adult; Aged; Aged, 80 and over; Area Under Curve; Arthroplasty, Replacement, Hip; Benzimidazoles; Cross-Over Studies; Dabigatran; Drug Interactions; Female; Food-Drug Interactions; Humans; Male; Metabolic Clearance Rate; Middle Aged; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Pyridines; Sulfoxides; Thrombin | 2005 |
Pharmacokinetics and pharmacodynamics of the direct oral thrombin inhibitor dabigatran in healthy elderly subjects.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Aged; Aged, 80 and over; Anti-Ulcer Agents; Anticoagulants; Area Under Curve; Benzimidazoles; Biological Availability; Blood Coagulation; Capsules; Chromatography, Liquid; Dabigatran; Diarrhea; Female; Flatulence; Hematoma; Humans; Male; Metabolic Clearance Rate; Pantoprazole; Partial Thromboplastin Time; Pyridines; Sex Factors; Tandem Mass Spectrometry; Thrombin | 2008 |
In vitro and in vivo evaluation of drug-drug interaction between dabigatran and proton pump inhibitors.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; ATP Binding Cassette Transporter, Subfamily B, Member 1; Caco-2 Cells; Cell Line, Tumor; Cyclosporine; Dabigatran; Drug Interactions; Humans; Lansoprazole; Male; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Rabeprazole; Thrombin; Young Adult | 2015 |
5 other study(ies) available for dabigatran and pantoprazole
| Article | Year |
|---|---|
Discovery of potent, selective multidrug and toxin extrusion transporter 1 (MATE1, SLC47A1) inhibitors through prescription drug profiling and computational modeling.
Topics: Computer Simulation; Fluorescent Dyes; Organic Cation Transport Proteins; Prescription Drugs | 2013 |
[Exfoliative esophagitis while taking dabigatran].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Anti-Ulcer Agents; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Endoscopy, Digestive System; Esophagitis; Female; Fluid Therapy; Humans; Hypertension; Pantoprazole | 2015 |
Dabigatran levels in omeprazole versus pantoprazole-treated patients with atrial fibrillation: is there a difference?
Topics: Aged; Aged, 80 and over; Antithrombins; Atrial Fibrillation; Dabigatran; Drug Interactions; Female; Humans; Male; Middle Aged; Omeprazole; Pantoprazole; Pilot Projects; Prospective Studies; Proton Pump Inhibitors | 2019 |
The Effect of Proton Pump Inhibitor Withdrawal on Dabigatran Etexilate Plasma Levels in Patients With Atrial Fibrillation: A Washout Study.
Topics: Aged; Aged, 80 and over; Antithrombins; Atrial Fibrillation; Dabigatran; Drug Administration Schedule; Drug Interactions; Drug Monitoring; Female; Humans; Male; Middle Aged; Omeprazole; Pantoprazole; Pilot Projects; Prospective Studies; Proton Pump Inhibitors; Time Factors; Treatment Outcome | 2020 |
Effect of Sex, Use of Pantoprazole and Polymorphisms in SLC22A1, ABCB1, CES1, CYP3A5 and CYP2D6 on the Pharmacokinetics and Safety of Dabigatran.
Topics: Adolescent; Adult; Anticoagulants; Antithrombins; Area Under Curve; ATP Binding Cassette Transporter, Subfamily B; Carboxylic Ester Hydrolases; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Dabigatran; Female; Genotype; Humans; Male; Middle Aged; Organic Cation Transporter 1; Pantoprazole; Pharmacogenetics; Polymorphism, Genetic; Proton Pump Inhibitors; Sex Factors; Spain; Thrombosis; Young Adult | 2020 |